University Clinical Hospital Mostar is the largest hospital in Mostar, Bosnia and Herzegovina. It is situated in the Bijeli Brijeg neighbourhood of the city, although Clinic for infectious diseases, ...

During the past decade, University Clinical Hospital Mostar conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 7 clinical trials were completed, i.e. on average, 43.8% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 6 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Clinical Hospital Mostar" #1 sponsor was "Celgene" with 3 trials, followed by "Takeda" with 3 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 2 trials sponsored and "SetPoint Medical Corporation" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Clinical Hospital Mostar" #1 collaborator was "Gilead Sciences" with 1 trials as a collaborator, "Orient Europharma Co., Ltd." with 1 trials as a collaborator and "Teva Branded Pharmaceutical Products R&D, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "University Clinical Hospital Mostar" are "Rheumatoid Arthritis" (4 trials), "Crohn Disease" (3 trials), "Crohn's Disease" (3 trials), "Colitis, Ulcerative" (2 trials) and "Pulmonary Arterial Hypertension" (2 trials). Many other conditions were trialed in "University Clinical Hospital Mostar" in a lesser frequency.

Most popular intervention types in "University Clinical Hospital Mostar" are "Drug" (20 trials), "Biological" (2 trials), "Device" (2 trials), "Other" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Ozanimod" (3 trials), "Cyberonics VNS System" (2 trials), "Guselkumab" (2 trials) and "ALRN-6924" (1 trials). Other intervention names were less common.

The vast majority of trials in "University Clinical Hospital Mostar" are 22 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University Clinical Hospital Mostar". 1 are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in University Clinical Hospital Mostar, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University Clinical Hospital Mostar, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".